HGM2002 Poster Abstracts: 8. Disease Mechanisms
POSTER NO: 398
CYP1A1 Gene Polymorphism and Risk of Epithelial Ovarian Neoplasm
Mehmet Alikasifoglu, Inci Guney, Dilek Aktas, Kunter Yuce, Ali Ayhan, Ergul Tuncbilek
Gene-environment interactions have been the focus of a number of recent studies of the occurrence of human cancers and an association between the risk and the CYP1A1*3 polymorphism has been noticed for several cancers. Previously studies suggest that estrogens are involved in the etiology of ovarian cancer. The CYP1A1 gene polymorphism may play role in the development of epithelial ovarian neoplasm by detoxification of polycyclic hydrocarbons and other compounds, and the concentration of estrogens and their metabolites. Therefore, we assessed the association of CYP1A1 gene polymorphism in patients with epithelial ovarian neoplasm in Turkish populations through a case control study. Using allele-specific polymerase chain reaction (PCR)-based method; CYP1A1*3 polymorphism, in exon 7 of the gene, was analysed in 117 epithelial ovarian neoplasm patients and 202 control subjects. The CYP1A1 Ile/Val genotype significantly increased the risk for patients with epithelial ovarian neoplasm (OR:5.7, 95%CI:3,34-9,76). Furthermore, there were statistical differences in the distribution of CYP1A1 Val/Val genotype among all patients (OR: 5,85; 95%CI: 2.40-14,25). In other words, the presence of Val allele significantly increased the risk of epithelial ovarian neoplasm. Among benign tumors, the frequency of Ile/Val and Val/Val genotypes were found to be statistically significant with an ORs of 6,01 and 4,38 (95%CI: 2.61-13.84 and 95%CI:1.04-18.38). In the benign serous ovarian tumours, patients with Ile/Val and Val/Val revealed a 7,2 and 10,5-fold higher risk of having ovarian carcinoma (95%CI:2.22-23.40 and 95%CI:2.16-51.19), respectively. In the benign mucinous ovarian carcinoma patients, the frequency of Ile/Val was found to be statistically significant with an OR of 5,15 (95%CI:1.75-15.16). However, no patient with Val/Val genotype was observed in this group and no statistical distribution was done. Among borderline tumors, CYP1A1 Ile/Val genotype significantly increased the risk for patients (OR:5.15, 95%CI:1.75-15.16). However, only a patient was observed with Val/Val allele and the frequency of this genotype was not found to be statistically different with an OR of 2.50 (95%CI: 0.27-22,64). Among ovarian cancer patients, there were statistical differences in the distribution of CYP1A1 Ile/Val and Val/Val genotypes (OR:5.73, 95%CI: 3.04-10.76 and OR:7,42, 95%CI: 2.80-19.66), suggesting that patients carrying these genotypes were at increased risk for ovarian carcinoma. In serous carcinoma, patients with CYP1A1 Ile/Val and Val/Val revealed a 6.5- and 10-fold higher risk of having ovarian cancer (OR: 7.09, 95%CI:3.30-15.22 and OR: 8.77, 95%CI: 2.83-27.14). In mucinous carcinoma, patients with CYP1A1 Ile/Val and Val/Val also revealed a 5,4- and 10,5-times higher risk of having ovarian cancer. There were no statistically significant differences in the distribution of Val allele among endometroid type cancer patients. Conclusions: Our data, although based on a small number of subjects, suggests that CYP1A1 gene polymorphism should be used as a predictive important risk modifier in the development of eopthelial neoplasms.
Other abstracts in same session